This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.
Mechanism of Action
Pathological Context
FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology[@kwiatkowski2009][@vance2009]. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.
Key pathological features:
Nuclear export dysregulation: FUS mutations impair nuclear localization signals (NLS), leading to cytoplasmic accumulation[@dormann2010]
This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.
Mechanism of Action
Pathological Context
FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology[@kwiatkowski2009][@vance2009]. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.
Key pathological features:
Nuclear export dysregulation: FUS mutations impair nuclear localization signals (NLS), leading to cytoplasmic accumulation[@dormann2010]
Primary Mechanism: Reduce FUS expression using RNA-targeting approaches (ASO, RNAi) or enhance FUS clearance through [autophagy](/entities/autophagy) enhancement.
Secondary Mechanism: Target stress granule dynamics using small molecules that promote granule dissolution without blocking protective stress response.
Tertiary Mechanism: Nuclear import enhancement using nuclear localization signal (NLS) peptide conjugates or small molecule nuclear import enhancers.
Rubric Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 9 | First-in-class mechanism targeting FUS proteinopathy distinct from TDP-43 approaches | | Mechanistic Rationale | 8 | Strong genetic evidence (FUS mutations cause ALS6), pathology confirmed in sporadic cases | | Addresses Root Cause | 8 | Targets protein aggregation at source rather than downstream effects | | Delivery Feasibility | 6 | CNS delivery achievable via intrathecal ASO (proven in other ALS programs) | | Safety Plausibility | 7 | Allele-specific targeting possible for mutant FUS sparing wild-type function | | Combinability | 8 | Synergistic with TDP-43 targeted therapies, autophagy enhancers | | Biomarker Availability | 7 | CSF FUS levels, pNfH as neurodegeneration marker, FUS PET ligands in development | | De-risking Path | 7 | iPSC-derived [neurons](/entities/neurons) from FUS-ALS patients, FUS transgenic mouse models exist | | Multi-disease Potential | 8 | ALS, FTD, and rare FUS-linked encephalopathies | | Patient Impact | 8 | Addresses rapidly progressive motor neuron disease with high unmet need |
Total Score: 76/100
Preclinical Evidence
Genetic Evidence
FUS mutations cause ALS6 (autosomal dominant): P525L, R521C, R521H, R522G[@kwiatkowski2009][@vance2009]
FUS inclusions found in 5-10% of sporadic ALS cases
FUS-FTD represents ~10% of all FTD cases
Preclinical Models
FUS-ALS iPSC models: Motor neurons show cytoplasmic FUS mislocalization, stress granule persistence, and axonal transport defects[@tibshirani2016]
Transgenic mice: FUS P525L knock-in mice develop ALS phenotype with FUS inclusions[@tibshirani2016]
Cell models: FUS LLPS mutants show accelerated aggregation and reduced dissolution[@sharma2016][@murray2018]
Small Molecule Screening
Stress granule modulators: Several compounds identified that promote stress granule dissolution
[Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19350693/)
[Vance C, Rogelj B, Hortobágyi T, et al, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 (2009)](https://pubmed.ncbi.nlm.nih.gov/19350694/)
[Dormann D, Rodde R, Edbauer D, et al, ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import (2010)](https://pubmed.ncbi.nlm.nih.gov/20168091/)
[Sharma A, Lyakhovetsky V, Ok A, et al, ALS-associated FUS mutations lead to mechanical cracking of RNA stress granules (2016)](https://pubmed.ncbi.nlm.nih.gov/27845388/)
[Murray DT, Kato M, Lin Y, et al, Structure of FUS protein fibrils and its relevance to self-assembly and phase separation (2018)](https://pubmed.ncbi.nlm.nih.gov/29420199/)
[Tibshirani M, Tradewell ML, Mattedi K, et al, Cytoplasmic accumulation of FUS in motor neurons is sufficient to cause ALS-like phenotypes in mice (2016)](https://pubmed.ncbi.nlm.nih.gov/26555377/)
[Monahan Z, Shewmaker F, Pandey UB, Stress granules in ALS and FTD: emerging mechanistic insights (2016)](https://pubmed.ncbi.nlm.nih.gov/27343457/)
[Japtap J, Lanson EA, Jin IW, et al, FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage (2017)](https://pubmed.ncbi.nlm.nih.gov/28972080/)
Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving FUS Protein-Targeting Therapy for ALS/FTD discovered through SciDEX knowledge graph analysis: